14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of HALO
Powered by GPT-4o
Stock Analysis
Risk Assessment
Trading Strategy

Green day on Thursday for Halozyme Therapeutics stock after gaining 1.17%
(Updated on Jun 20, 2024)

Buy or Hold candidate since May 02, 2024 Gain 27.72% PDF

The Halozyme Therapeutics stock price gained 1.17% on the last trading day (Thursday, 20th Jun 2024), rising from $50.27 to $50.86. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 3.52% from a day low at $49.45 to a day high of $51.19. The price has been going up and down for this period, and there has been a 11.41% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 168 thousand more shares were traded than the day before. In total, 1 million shares were bought and sold for approximately $58.72 million.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 27.21% during the next 3 months and, with a 90% probability hold a price between $56.62 and $67.53 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

HALO Signals & Forecast

The Halozyme Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $49.93 and $45.39. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, June 06, 2024, and so far it has fallen -1.13%. Further fall is indicated until a new bottom pivot has been found.

Support, Risk & Stop-loss for Halozyme Therapeutics stock

Halozyme Therapeutics finds support from accumulated volume at $49.66 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.74 between high and low, or 3.52%. For the last week, the stock has had daily average volatility of 3.01%.

Our recommended stop-loss: $48.85 (-3.96%) (This stock has high daily movements and this gives high risk. The RSI14 is 78 and this increases the risk substantially. There is a sell signal from a pivot top found 43 days ago.)

Trading Expectations (HALO) For The Upcoming Trading Day Of Friday 21st

For the upcoming trading day on Friday, 21st we expect Halozyme Therapeutics to open at $50.50, and during the day (based on 14 day Average True Range), to move between $49.21 and $52.51, which gives a possible trading interval of +/-$1.65 (+/-3.23%) up or down from last closing price. If Halozyme Therapeutics takes out the full calculated possible swing range there will be an estimated 6.47% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $51.16 (0.59%) than the support at $49.66 (2.36%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Halozyme Therapeutics stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Halozyme Therapeutics stock to perform well in the short-term.

Current score: 2.620 Buy Candidate Unchanged

Predicted Opening Price for Halozyme Therapeutics of Friday, June 21, 2024

Fair opening price June 21, 2024 Current price
$50.50 ( 0.708%) $50.86

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for HALO

Fibonacci Support & Resistance Levels

Level Price
R3 52.24 2.71%
R2 51.58 1.41%
R1 51.16 0.599%
Price 50.86
S1 49.84 -2.01%
S2 49.42 -2.82%
S3 48.76 -4.13%

Accumulated Volume Support & Resistance Levels

Level Price
R3 0 -
R2 51.44 1.14%
R1 51.16 0.590%
Price 50.86
S1 49.66 -2.36%
S2 42.01 -17.40%
S3 39.91 -21.53%


What is the symbol for Halozyme Therapeutics Stock and on which exchange is it traded?
The symbol for Halozyme Therapeutics is HALO and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Halozyme Therapeutics Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Halozyme Therapeutics stock to perform well in the short-term.

How to buy Halozyme Therapeutics Stock?
Halozyme Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Halozyme Therapeutics Stock.

What's the current price of Halozyme Therapeutics Stock?
As of the end of day on the Jun 20, 2024, the price of an Halozyme Therapeutics (HALO) share was $50.86.

What is the 52-week high and low for Halozyme Therapeutics Stock?
The 52-week high for Halozyme Therapeutics Stock is $52.74 and the 52-week low is $32.83.

What is the market capitalization of Halozyme Therapeutics Stock?
As of the Jun 20, 2024, the market capitalization of Halozyme Therapeutics is 6.398B.

When is the next earnings date for Halozyme Therapeutics?
The upcoming earnings date for Halozyme Therapeutics is Aug 13, 2024.
Click to get the best stock tips daily for free!

About Halozyme Therapeutics

Halozyme Therapeutics Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules a... HALO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE